Avecho Biotechnology Ltd (ASX: AVE) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Avecho Biotechnology Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $15.85 million
P/E Ratio 17.99
Dividend Yield 0.00%
Shares Outstanding 3.17 billion
Earnings per share -0.001
Dividend per share N/A
Year To Date Return 100.00%
Earnings Yield 5.56%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Avecho Biotechnology Ltd (ASX: AVE)
    Latest News

    a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
    Healthcare Shares

    Do ASX biotech shares offer 'good buying' after the sell-off? Experts weigh in

    After some strong support in early 2021, biotechnology stocks took a beating over the past 6 months.

    Read more »

    jump in asx share price represented by man leaping up from one wooden pillar to the next
    Share Market News

    Avecho (ASX:AVE) share price rockets 83% on milestone announcement

    The Avecho Biotechnology Ltd (ASX: AVE) share price is beating the All Ordinaries Index (ASX: XAO) by a mile today.…

    Read more »

    AVE ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Avecho Biotechnology Ltd

    Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sales, and licensing of products incorporating its patented platform technology Tocopheryl Phosphate Mixture (TPM), for the pharmaceutical, skincare, and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.

    AVE Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    17 Apr 2025 $0.01 $0.00 0.00% 35,649 $0.00 $0.01 $0.00
    16 Apr 2025 $0.00 $0.00 0.00% 611,777 $0.00 $0.00 $0.00
    15 Apr 2025 $0.01 $0.00 0.00% 80,656 $0.00 $0.01 $0.00
    14 Apr 2025 $0.00 $0.00 0.00% 751,149 $0.01 $0.01 $0.00
    11 Apr 2025 $0.01 $0.00 0.00% 416,345 $0.00 $0.01 $0.00
    10 Apr 2025 $0.01 $0.00 0.00% 10,655,808 $0.01 $0.01 $0.00
    09 Apr 2025 $0.00 $0.00 0.00% 181,350 $0.00 $0.00 $0.00
    08 Apr 2025 $0.01 $0.00 0.00% 2,154,280 $0.00 $0.01 $0.00
    07 Apr 2025 $0.00 $0.00 0.00% 21,950,302 $0.00 $0.01 $0.00
    04 Apr 2025 $0.01 $0.00 0.00% 38,318,773 $0.01 $0.01 $0.01
    03 Apr 2025 $0.01 $0.00 0.00% 12,539,708 $0.01 $0.01 $0.01
    02 Apr 2025 $0.01 $0.00 0.00% 732,690 $0.01 $0.01 $0.01
    01 Apr 2025 $0.01 $0.00 0.00% 1,157,725 $0.01 $0.01 $0.01
    31 Mar 2025 $0.01 $0.00 0.00% 9,847,003 $0.01 $0.01 $0.01
    28 Mar 2025 $0.01 $0.00 0.00% 45,093,763 $0.01 $0.01 $0.01
    27 Mar 2025 $0.01 $0.00 0.00% 1,853,990 $0.01 $0.01 $0.01
    26 Mar 2025 $0.01 $0.00 0.00% 5,906,481 $0.01 $0.01 $0.01
    25 Mar 2025 $0.01 $0.00 0.00% 4,663,411 $0.01 $0.01 $0.01
    24 Mar 2025 $0.01 $0.00 0.00% 3,776,071 $0.01 $0.01 $0.01
    21 Mar 2025 $0.01 $0.00 0.00% 3,884,656 $0.01 $0.01 $0.01

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    29 Nov 2024 Gregory (Greg) Collier Expiry 5,990,465 $23,961
    Options expired.
    29 Nov 2024 Ross Murdoch Expiry 3,993,644 $15,974
    Options expired.
    29 Nov 2024 Matthew McNamara Expiry 3,993,644 $15,974
    Options expired.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Dr Gregory (Greg) Collier Non-Executive ChairmanNon-Executive Director Apr 2019
    Dr Collier has more than 25 years fo experience spanning operational, clinical and scientific aspects of pharmaceutical research, development and commercialization. Dr Collier has led the planning and execution of multiple commercial transactions including in and out licensing deals and major M&A activities, and he has taken a drug from discovery through to regulatory approval. Notably, Dr Collier steered ChemGenex Pharmaceuticals Limited from a research-based Company with a market capitalisation of $10 million to a Company with completed clinical trials and regulatory dossiers submitted to the FDA and EMA. In 2011, ChemGenex was sold to Cephalon Inc. (now subsidiary of Teva Pharmaceuticals Industries Limited) for $230 million. Prior to his commercial pharmaceutical career, Dr Collier had an academic career resulting in over 150 peer reviewed publications, and senior authorship on 33 patents.
    Dr Ross Murdoch Non-Executive Director Apr 2015
    Dr Murdoch has over 30 years of experience as a leader within the global healthcare, pharmaceutical and biotechnology industries. He has held senior management and executive positions in Australia, the USA and Europe, with responsibility for the strategy, development and commercialization of products, product portfolios and the building and rebuilding of new and existing businesses. Highlights of his career include Senior Vice President at Shire Pharmaceuticals, based in the USA and Switzerland, where he founded and grew both the Emerging Products Business and Haematology Business and President and COO of Prana Biotechnology Limited based in Australia.
    Mr Matthew Patrick McNamara Non-Executive Director Jan 2020
    Mr McNamara has over 30 years of executive and funds management experience in the healthcare and medical sciences sector. In 2003, he founded BioBridge Australia, a biotechnology commercialization advisory company and advised a number of public biotechnology / investment companies. Mr McNamara is currently Director and Chief Investment Officer of Horizon 3 Healthcare, a healthcare fund manager that has invested in Avecho Biotechnology Limited through trustee Melbourne Securities Corporation Limited.
    Ms Katherine(Kathy) Ellen Danielle Connell Non-Executive Director Apr 2024
    Ms. Connell is a commercial executive with business development expertise across pharmaceutical, vaccine, medtech, consumer and digital health industries. Ms. Connell is currently Senior Client Partner and Head of Healthcare and Life Sciences Australia/New Zealand at Korn Ferry. For the past 20 years, Ms Connell has held senior executive leadership positions in biotechnology, pharmaceutical, medical device and consumer health sectors specializing in business development, licensing, acquisitions and venture investment, including 12 years at Johnson & Johnson as Senior Director, New Ventures ANZ.
    Ms Melanie Jaye Leydin Chief Financial OfficerCompany Secretary Dec 2018
    -
    Dr Paul Gavin Chief Executive Officer May 2020
    -
    Paul Gavin Chief Executive Officer
    -
    Melanie Jaye Leydin Chief Financial OfficerCompany Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Mr Mark Gregory Kerr & Mrs Linda Marie Kerr <Lindmark Inv Staff S/F A/C> 349,133,188 11.02%
    Ms Chunyan Niu 252,000,000 7.95%
    Rosscope Pty Ltd <Ross Copeland Family A/C> 85,513,129 2.70%
    Melbourne Securities Corporation Limited <Horizon 3 Biotech Fund A/C> 59,345,624 1.87%
    HSBC Custody Nominees (Australia) Limited 58,323,186 1.84%
    Jawess Pty Ltd <Kent Family Super Fund A/C> 50,000,000 1.58%
    Servbond Pty Limited <Servbond Pty Ltd S/F A/C> 47,000,000 1.48%
    Mr Brandon Armon Batagol 44,532,406 1.41%
    10 Bolivianos Pty Ltd 43,796,359 1.38%
    SKED Proprietary Limited <SKED Superannuation Fund A/C> 42,000,000 1.33%
    Melbourne Securities Corporation Limited <Horizon 3 Healthcare A/C> 41,666,666 1.31%
    BNP Paribas Noms Pty Ltd 39,367,251 1.24%
    Dr Maurice Arthur Trewhella & Mrs Elizabeth Trewhella <Simpetejen Super Fund A/C> 30,000,000 0.95%
    Scintilla Strategic Investments Limited 30,000,000 0.95%
    Citicorp Nominees Pty Limited 28,336,058 0.89%
    Dr Stephen Dennis Gipps 26,000,000 0.82%
    King Corporate Pty Ltd 25,333,333 0.80%
    Ashmat Investments Pty Ltd <Hester Investment A/C> 25,000,000 0.79%
    Mr David Segal 23,000,000 0.73%
    Mr Bin Liu 22,780,039 0.72%

    Profile

    since

    Note